Cytosine Deaminase/5-Fluorocytosine-Based Vaccination Against Liver Tumors: Evidence of Distant Bystander Effect
Open Access
- 1 December 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 91 (23) , 2014-2019
- https://doi.org/10.1093/jnci/91.23.2014
Abstract
BACKGROUND: The cytosine deaminase gene of Escherichia coli converts the nontoxic compound 5-fluorocytosine into 5-fluorouracil (5-FU), thereby acting as a suicide gene when introduced into cancer cells, killing the cells when they are exposed to 5-fluorocytosine. We analyzed the efficacy of using cytosine deaminase-bearing cancer cells as an autologous tumor vaccine in a rat model that mimics liver metastasis from colon carcinoma. METHODS: We introduced a plasmid vector containing the E. coli cytosine deaminase gene into a BDIX rat colon carcinoma cell line. Intrahepatic injection of the modified cells in syngeneic animals generates a single experimental liver “suicide tumor.” We then analyzed the effect of 5-fluorocytosine treatment in terms of regression of cytosine deaminase-expressing cells in vivo as well as protection against wild-type cancer cells. RESULTS: Treatment with 5-fluorocytosine induced regression of cytosine deaminase-expressing (CD+) tumors, with seven of 11 treated animals being tumor free at the end of 30 days and a statistically significant difference in tumor volumes between treated and control animals (two-sided P <.0001). Intrahepatic injection of CD+ cells followed by 5-fluorocytosine treatment rendered the treated animals resistant to challenge with wild-type tumor cells, with no (zero of seven) treated animals developing wild-type tumors in contrast to all (four of four) control animals. Moreover, in animals with established wild-type liver tumors, injection of CD+ tumor cells followed by 5-fluorocytosine treatment produced a statistically significant increase in survival time (two-sided P <.0001). In vivo immunodepletion and immunohistologic analysis of experimental tumors indicate that natural killer cells are the major immune component involved in this antitumor effect. CONCLUSIONS and IMPLICATIONS: Taken together, these results suggest the potential use of suicide gene-modified tumor cells as therapeutic vaccines against liver metastasis from colon carcinoma.Keywords
This publication has 12 references indexed in Scilit:
- A “Distant” Bystander Effect of Suicide Gene Therapy: Regression of Nontransduced Tumors Together with a Distant Transduced TumorHuman Gene Therapy, 1997
- Suicide gene therapy for plasma cell tumorsBlood, 1996
- NK1.1+ T cell receptor-alpha/beta+ cells: new clues to their origin, specificity, and function.The Journal of Experimental Medicine, 1995
- 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory.The Journal of Immunology, 1995
- Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.Proceedings of the National Academy of Sciences, 1994
- Colon and rectum cancer. Patterns of spread and implications for workupCancer, 1993
- Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system.Proceedings of the National Academy of Sciences, 1992
- F11C antigen: A membrane marker able to distinguish two regressive and progressive variants from a rat colon adenocarcinomaInternational Journal of Cancer, 1990
- Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumorsInternational Journal of Cancer, 1983
- Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma.Clinical Chemistry, 1979